Peer-reviewed veterinary case report
How CAR T-cell therapy is managed for large B-cell lymphoma in France
By Thieblemont C et al.·2026·Université Paris Cité, France·View original on Europe PMC →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).
Plain-English summary
This study looked at how patients with Large B-cell Lymphoma (a type of cancer) were treated with CAR T-cell therapy in France from 2018 to 2023. It found that patients receiving this treatment for the second time had shorter hospital stays compared to those getting it later on. The type of CAR T-cell product also made a difference; one product led to shorter stays and fewer trips to the intensive care unit than another. Overall, the experience of the hospital played a big role in how well patients did, with more experienced centers helping patients leave the hospital sooner. The findings suggest that the quality of care for CAR T-cell therapy is significantly influenced by the hospital's expertise.
Abstract
This study describes the inpatient care pathway for 1914 Large B-cell Lymphoma (LBCL) patients treated with CAR T-cell therapy in France between 2018 and 2023 and identifies factors influencing their management. Based on a retrospective analysis of the French national hospital database, we found the average CAR T-cell infusion stay was shorter for patients in the second line of treatment <i>versus</i> later lines (20.4 <i>vs.</i> 23.8 days). The specific product used was also influential; for example, lisocabtagene maraleucel was associated with shorter stays and fewer ICU admissions than axicabtagene ciloleucel. A multivariate analysis confirmed that while patient characteristics and the CAR T-cell product influenced outcomes, higher center experience was a primary determinant. More experienced centers had shorter hospital stays and a higher probability of patients being discharged home, demonstrating that the management of CAR T-cell patients is largely dependent on institutional experience.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Europe PMC: https://europepmc.org/article/MED/42052989